

***Fiscal Year 2022 (FY22) Combat Readiness – Medical Research Program (CRRP)  
Reference Table of Award Mechanism and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Rapid Development and Translational Research Award (RDTRA)</b></p> <p><i>Extramural applicants:</i> Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Broad Agency Announcement</a></li> <li>• <a href="#">General Submission Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-22-S-CRRP</a></p> <p><i>Intramural applicants:</i> Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> </ul> <p><b>eBRAP.org Funding Opportunity Number:</b> W81XWH-22-CRRP-RDTRA</p>	<p><b>Extramural and intramural applicants:</b></p> <ul style="list-style-type: none"> <li>• Independent investigators at all academic levels (or equivalent)</li> </ul>	<ul style="list-style-type: none"> <li>• <i>Submission of a preproposal is required; application submission is by invitation only.</i></li> <li>• Supports high-impact research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines.</li> <li>• Proposed research must have the potential for rapid development and translation of applicable advances for improving medical readiness, mitigating fatalities, optimally treating life-threatening injuries, and promoting positive long-term outcomes for military health and medicine, as well as the general public.</li> <li>• Supports preclinical research, clinical research, and small-scale clinical trials (e.g., first in human, phase 1/1b). Fundamental basic research and phase 2/3 clinical trials are not supported under this funding opportunity.</li> <li>• Proposed research <i>must</i> address at least one of the FY22 CRRP Focus Areas.</li> <li>• Different funding options are available. Applicants may apply for either the RDTRA, or the RDTRA with Option. It is the responsibility of the Principal Investigator to select the funding option that is most appropriate for the research proposed. <ul style="list-style-type: none"> <li>○ For applications proposing an RDTRA with Option, each phase of research must be a distinct research effort with non-overlapping period of performance, research outcomes/milestones, and budget. Research products from the first phase of performance shall be leveraged in the subsequent Option phase.</li> <li>○ Exercise of the Option is contingent on the availability of sufficient future congressional appropriations to the CRRP, alignment of the proposed research during the Option to that fiscal year’s congressional language, and acceptable performance by the recipients.</li> </ul> </li> </ul>	<p><b>RDTRA:</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$2,200,000</b> for total costs (to include direct and indirect costs).</li> <li>• Maximum period of performance is <b>2 years</b>.</li> </ul> <p><b>RDTRA with Option:</b></p> <ul style="list-style-type: none"> <li>• Maximum funding of <b>\$2,200,000</b> (RDTRA) and <b>1,000,000</b> (Option) for total costs (to include direct and indirect costs).</li> <li>• Maximum period of performance is <b>2 years</b> for the first phase of performance of the RDTRA and <b>1 year</b> for the Option.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 23, 2022 5:00 p.m. Eastern Time</p> <p><b>Proposal/Application:</b> September 14, 2022 11:59 p.m. Eastern Time</p>